Literature DB >> 17487900

Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.

Richard J Payne1, Fabienne Peyrot, Olivier Kerbarh, Andrew D Abell, Chris Abell.   

Abstract

The in silico design, synthesis, and biological evaluation of ten potent type II dehydroquinase inhibitors are described. These compounds contain an anhydroquinate core, incorporated as a mimic of the enolate reaction intermediate. This substructure is attached by a variety of linking units to a terminal phenyl group that binds in an adjacent pocket. Inhibitors were synthesised from (-)-quinic acid using palladium-catalysed Stille and carboamidation chemistry. Several inhibitors exhibited nanomolar inhibition constants against type II dehydroquinases from Streptomyces coelicolor and Mycobacterium tuberculosis. These are among the most potent inhibitors of these enzymes reported to date.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487900     DOI: 10.1002/cmdc.200700032

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  5 in total

1.  New molecular scaffolds for the design of Mycobacterium tuberculosis type II dehydroquinase inhibitors identified using ligand and receptor based virtual screening.

Authors:  Ashutosh Kumar; Mohammad Imran Siddiqi; Stanislav Miertus
Journal:  J Mol Model       Date:  2009-10-09       Impact factor: 1.810

2.  Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders.

Authors:  Paulo H de S Miranda; Estela M G Lourenço; Alexander M S Morais; Pedro I C de Oliveira; Priscilla S de S N Silverio; Alessandro K Jordão; Euzébio G Barbosa
Journal:  Mol Divers       Date:  2019-12-09       Impact factor: 2.943

3.  Resistance in tuberculosis: what do we know and where can we go?

Authors:  Keith D Green; Sylvie Garneau-Tsodikova
Journal:  Front Microbiol       Date:  2013-07-23       Impact factor: 5.640

Review 4.  Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

Authors:  José E S Nunes; Mario A Duque; Talita F de Freitas; Luiza Galina; Luis F S M Timmers; Cristiano V Bizarro; Pablo Machado; Luiz A Basso; Rodrigo G Ducati
Journal:  Molecules       Date:  2020-03-11       Impact factor: 4.411

5.  Type II dehydroquinase: molecular replacement with many copies.

Authors:  Kirsty Anne Stewart; David Alexander Robinson; Adrian Jonathan Lapthorn
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.